Comparison
Wegovy vs Compounded Semaglutide 2026: Same Molecule, Different Product
Same active molecule. Different product. Wegovy is an FDA-approved finished product with STEP-1 and SELECT behind it, at $349 through NovoCare or $149 for the oral tablet
Same active molecule. Different product. Wegovy is an FDA-approved finished product with STEP-1 and SELECT behind it, at $349 through NovoCare or $149 for the oral tablet. Compounded semaglutide is $145 to $178 captured at source, has no trial of its own, and may use a salt form the FDA has said is not appropriate for compounding.
What is identical, and what is not?
| Field | Brand Wegovy | Compounded semaglutide |
|---|---|---|
| Active molecule | Semaglutide | Semaglutide base, or a salt form |
| FDA-approved finished product | Yes | No |
| Trial evidence for this product | STEP-1: 14.9%. SELECT: 20% MACE reduction | None. The figures quoted alongside it were collected on the approved product |
| Manufacturing oversight | cGMP, FDA-inspected | 503A state board, or 503B FDA-registered |
| Self-pay monthly | $349 (NovoCare) or $149 (oral tablet) | $145–$178 captured |
| Dose flexibility | Fixed pen doses | Vial, dose-flexible |
| Regulatory risk | None current | Live: the FDA proposed excluding semaglutide from the 503B bulks list on 30 April 2026 |
The molecule is the same. The product in your hand was never in a trial.
That does not make compounded semaglutide ineffective, and we do not claim it does. It means the evidence being shown to you was gathered on something else, and the strength of that evidence does not travel with the molecule across a change of manufacturer, formulation or salt form.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Is the compounded route still meaningfully cheaper?
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Commercial coverage plus savings card | $0–$25 | $0–$300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Compounded, 12-month, flat | $145 | $1,740 | Captured at source |
| Oral Wegovy tablet, self-pay | $149 | $1,788 | Provider-reported |
| Compounded, month-to-month, flat | $165 | $1,980 | Captured at source |
| Compounded plus membership | $178 | $2,136 | Captured at source |
| Brand Wegovy, NovoCare | $349 | $4,188 | Provider-reported |
| Brand Ozempic, retail cash | ~$998 | ~$11,976 | Third-party claim |
At $145 against $149, the reason to choose compounded is no longer price. It is dose flexibility, or availability, or the absence of a prior-authorisation fight. Those are real reasons. Price is no longer one of them for most buyers.
What is the salt-form question?
Its sodium and acetate salts are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. A salt form is a different chemical entity; it has not been through the safety or efficacy review the base went through.
Ask for the exact salt form and concentration in writing before you buy. A provider that cannot answer in writing has told you something. There is no tirzepatide equivalent of this question, which is why it belongs on every semaglutide page and on none of the tirzepatide ones.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Is compounded semaglutide the same as Wegovy?
Same molecule, different product. Wegovy is an FDA-approved finished product with STEP-1 and SELECT behind it. Compounded semaglutide has no trial of its own and may use a salt form.
Is Wegovy more expensive than compounded semaglutide?
Barely. Brand Wegovy is $349 through NovoCare but the approved oral tablet is $149, against $145 for the cheapest compounded programme we captured.
Does trial evidence apply to compounded semaglutide?
No. STEP-1 and SELECT studied the FDA-approved product. No trial has tested a compounded preparation.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Zepbound vs Compounded TirzepatidePillar / Money
- Zepbound vs Compounded TirzepatideComparisons
- Ro Body vs Mochi HealthComparisons
- NexLife vs Ro BodyComparisons
- Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal
- Brand-Name vs Compounded GLP-1Comparisons
- Hims & Hers vs Henry MedsComparisons
Related coverage
Semaglutide Ranked. “Wegovy vs Compounded Semaglutide 2026: Same Molecule, Different Product.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/wegovy-vs-compounded-semaglutide-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.